Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ICMT | O60725 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5726787 | 0.85 | HPGD (0.49) | MEN1KMT2AHPGDMAPTHTT | |
| Hydrochloric Acid SCHEMBL4683451 | 0.83 | HPGD (0.47) | MEN1KMT2AHPGDMAPTHTT | |
| SCHEMBL7214532 | 0.82 | MAPT (0.47) | MEN1KMT2AHPGDMAPTHTT | |
| SCHEMBL4167975 | 0.81 | MEN1 (0.53) | MEN1KMT2AHPGDMAPTHTT | |
| SCHEMBL1431624 | 0.81 | MEN1 (0.53) | MEN1KMT2AHPGDMAPTHTT | |
| SCHEMBL6235610 | 0.81 | MAPT (0.50) | MEN1KMT2AHPGDMAPTHTT | |
| Hydrochloric Acid SCHEMBL5857094 | 0.79 | MAPT (0.48) | MEN1KMT2AHPGDMAPTHTT | |
| SCHEMBL11119734 | 0.79 | ALDH1A1 (0.68) | MEN1KMT2AHPGDMAPTHTT | |
| SCHEMBL11935735 | 0.79 | MAPT (0.44) | MEN1KMT2AHPGDMAPTHTT | |
| SCHEMBL12355294 | 0.78 | MEN1 (0.55) | MEN1KMT2AHPGDMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411362-B1 | Tricyclic indole derivatives as PBR ligands | GE HEALTHCARE LTD (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-9314541-B2 | In vivo imaging method for cancer | GE HEALTHCARE LIMITED (GB) | 2016-04-19 | — | — | US | disclosed |
| US-9220795-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2015-12-29 | — | — | US | disclosed |
| US-9168317-B2 | In vivo imaging method of mood disorders | GE HEALTHCARE LIMITED (GB) | 2015-10-27 | — | — | US | disclosed |
| US-20140364615-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2014-12-11 | — | — | US | disclosed |
| US-8790619-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2014-07-29 | — | — | US | disclosed |
| EP-2618850-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE Healthcare UK Limited (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2013-07-18 | — | — | US | disclosed |
| CN-103209713-A | In vivo imaging method of mood disorders | GE HEALTHCARE LTD | 2013-07-17 | — | — | CN | disclosed |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE HEALTHCARE LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| CN-103179991-A | In vivo imaging method for cancer | GE HEALTHCARE LTD | 2013-06-26 | — | — | CN | disclosed |
| CN-102448933-A | Indole Derivatives as PBR Ligands | GE HEALTHCARE LTD | 2012-05-09 | — | — | CN | disclosed |
| WO-2012038532-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| EP-2411362-A2 | INDOLE DERIVATIVES | GE Healthcare UK Limited (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-20120020884-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| WO-2010109007-A2 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020884-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | MEN1 334/4885KMT2A 326/4885HPGD 2353/4885 |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | MKI67, PBRM1, BRD4 | MEN1 1142/4885KMT2A 1543/4885HPGD 308/4885 |
| US-20140364615-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | MEN1 334/4885KMT2A 326/4885HPGD 2353/4885 |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | SLC18A2, SLC6A2, SLC6A4 | MEN1 832/4885KMT2A 573/4885HPGD 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.